Stemchymal
Phase 2- Indications
- Spinocerebellar ataxia
Company intelligence / Profile preview
REPROCELL
Yokohama, Japanreprocell.com ↗
- Ownership
- Public · 4978
- Development stage
- Phase 2
01
Overview
REPROCELL’s partnered MSC product "Stemchymal" has shown positive Phase II results in Taiwan and Japan for spinocerebellar ataxia. The company’s iPSC-derived GRP program has demonstrated efficacy in preclinical models of ALS and transverse myelitis. Gameto's Fertilo program using REPROCELL’s iPSCs received FDA IND clearance to enter U.S. Phase 3 trials
- Therapeutic areas
- OtherNeurology
- Modalities
- Induced pluripotent stem cell derived therapyMesenchymal stem cell therapyCell therapyGene editing (CRISPR-based)Oligonucleotide synthesis
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Steminent Biotherapeutics Inc. (co-development/commercialization of Stemchymal)Q Therapeutics Inc. (collaboration on GRP therapies)Gameto Inc. (iPSC supply/technology partnership)
04
Financials
- Market cap
- $71.5M
- Total revenue
- $14.1M
- Enterprise value
- $36M
Beyond the preview
Go deeper on REPROCELL.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REPROCELL.